{"id":3945,"date":"2025-03-31T18:11:53","date_gmt":"2025-03-31T18:11:53","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/eplerenone-txt\/"},"modified":"2025-03-31T18:11:53","modified_gmt":"2025-03-31T18:11:53","slug":"eplerenone-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/eplerenone-txt\/","title":{"rendered":"Eplerenone.txt"},"content":{"rendered":"

Eplerenone<\/h1>\n

CLINICAL USE <\/H3>
\nAldosterone antagonist:Left ventricular dysfunction and heart failure

DOSE IN NORMAL RENAL FUNCTION <\/H3> 25\u201350 mg daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :414.5<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :50<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <5<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :43\u201357 litres<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :3\u20136

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function1
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function1
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function1

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :10% dialysed.1 Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR=10-20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsACE inhibitors or AT-II antagonists: enhanced hypotensive effect; risk of severe hyperkalaemia\n
  • Anti-arrhythmics: concentration increased by amiodarone \u2013 reduce eplerenone dose\n
  • Antibacterials: concentration increased by clarithromycin and telithromycin \u2013 avoid concomitant use; concentration increased by erythromycin \u2013 reduce eplerenone dose; concentration reduced by rifampicin \u2013 avoid concomitant use; avoid concomitant use with lymecycline; increased risk of hyperkalaemia with trimethoprim\n
  • Antidepressants: concentration reduced by St John\u2019s wort \u2013 avoid concomitant use; increased risk of postural hypotension with tricyclics; enhanced hypotensive effect with MAOIs\n
  • Anti-epileptics: concentration reduced by carbamazepine, phenytoin and phenobarbital \u2013 avoid concomitant use\n
  • Antifungals: concentration increased by itraconazole and ketoconazole \u2013 avoid concomitant use; concentration increased by fluconazole \u2013 reduce eplerenone doseAntihypertensives: enhanced hypotensive effect, increased risk of first dose hypotensive effect with post-synaptic alpha-blockers\n
  • Antivirals: concentration increased by nelfinavir and ritonavir \u2013 avoid concomitant use; concentration increased by saquinavir \u2013 reduce eplerenone dose\n
  • Ciclosporin: increased risk of hyperkalaemia and nephrotoxicityNSAIDs: increased risk of hyperkalaemia (especially with indometacin); increased risk of nephrotoxicity; antagonism of diuretic effect\n
  • Potassium salts: increased risk of hyperkalaemia\n
  • Lithium: reduced lithium excretion \u2013 avoid concomitant use\n
  • Tacrolimus: increased risk of hyperkalaemia and nephrotoxicityCYP3A4 inhibitors: Do not exceed a dose of 25 mg daily for eplerenoneCYP3A4 inducers: reduced eplerenone concentration \u2013 avoid concomitant use

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Monitor potassium levels regularly in people with renal impairment
    \n","protected":false},"excerpt":{"rendered":"

    Eplerenone CLINICAL USE Aldosterone antagonist:Left ventricular dysfunction and heart failure<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3945","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3945","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3945"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3945\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3945"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3945"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3945"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}